The lung in primary immunodeficiencies: New concepts in infection and inflammation

Ulrich Baumann, John M. Routes, Pere Soler-Palacín, Stephen Jolles

    Research output: Contribution to journalReview articleResearchpeer-review

    44 Citations (Scopus)


    © 2018 Baumann, Routes, Soler-Palacín and Jolles. Immunoglobulin replacement therapy (IGRT) has contributed critically to the management of primary antibody deficiencies (PAD) and the decrease in pneumonia rate. However, despite adequate IGRT and improved prognosis, patients with PAD continue to experience recurrent respiratory tract infections, leading to bronchiectasis and continuing decline in lung function with a severe impact on their quality of life. Moreover, non-infectious inflammatory and interstitial lung complications, such as granulomatous-lymphocytic interstitial lung disease, contribute substantially to the overall morbidity of PAD. These conditions develop much more often than appreciated and represent a major therapeutic challenge. Therefore, a regular assessment of the structural and functional condition of the lung and the upper airways with appropriate treatment is required to minimize the deterioration of lung function. This work summarizes the knowledge on lung complications in PAD and discusses the currently available diagnostic tools and treatment options.
    Original languageEnglish
    Article number1837
    JournalFrontiers in immunology
    Issue numberAUG
    Publication statusPublished - 8 Aug 2018


    • Bronchiectasis
    • Comorbidity
    • Granulomatous-lymphocytic interstitial lung disease
    • Immunoglobulin
    • Lung complications
    • Lung computed tomographic scan
    • Primary immunodeficiency
    • Pulmonary functional tests


    Dive into the research topics of 'The lung in primary immunodeficiencies: New concepts in infection and inflammation'. Together they form a unique fingerprint.

    Cite this